MX392158B - Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). - Google Patents
Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).Info
- Publication number
- MX392158B MX392158B MX2017012397A MX2017012397A MX392158B MX 392158 B MX392158 B MX 392158B MX 2017012397 A MX2017012397 A MX 2017012397A MX 2017012397 A MX2017012397 A MX 2017012397A MX 392158 B MX392158 B MX 392158B
- Authority
- MX
- Mexico
- Prior art keywords
- ache
- recognizes
- peptide
- antibody
- acetylcholinesterase enzyme
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1505239.2A GB201505239D0 (en) | 2015-03-27 | 2015-03-27 | Antibody |
| GB1600871.6A GB2541477A (en) | 2015-03-27 | 2016-01-18 | Antibody |
| PCT/GB2016/050804 WO2016156803A1 (en) | 2015-03-27 | 2016-03-23 | Antibody that recognises the t14 peptide of ache |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017012397A MX2017012397A (es) | 2018-01-26 |
| MX392158B true MX392158B (es) | 2025-03-21 |
Family
ID=53178191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012397A MX392158B (es) | 2015-03-27 | 2016-03-23 | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10954306B2 (enExample) |
| EP (1) | EP3274371B1 (enExample) |
| JP (1) | JP7327897B2 (enExample) |
| KR (1) | KR102626626B1 (enExample) |
| CN (1) | CN107531796A (enExample) |
| AU (1) | AU2016240020B2 (enExample) |
| BR (1) | BR112017020769A2 (enExample) |
| CA (1) | CA2979972A1 (enExample) |
| ES (1) | ES2952723T3 (enExample) |
| GB (2) | GB201505239D0 (enExample) |
| MX (1) | MX392158B (enExample) |
| RU (1) | RU2729491C2 (enExample) |
| WO (1) | WO2016156803A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2539161A (en) * | 2014-11-26 | 2016-12-14 | Neuro-Bio Ltd | Neurodegenerative disorders |
| GB2546773B (en) * | 2016-01-28 | 2020-06-17 | Neuro Bio Ltd | Cancer |
| GB201705044D0 (en) * | 2017-03-29 | 2017-05-10 | Neuro-Bio Ltd | Biomarker |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| GB202112831D0 (en) * | 2021-09-09 | 2021-10-27 | Neuro Bio Ltd | Biomarker |
| GB202113941D0 (en) | 2021-09-29 | 2021-11-10 | Neuro Bio Ltd | Skin biomarker |
| CA3267108A1 (en) | 2022-09-08 | 2024-03-14 | Neuro-Bio Ltd | LATERAL FLOW DEVICE FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE USING THE T14 PEPTIDE |
| GB202308779D0 (en) * | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Aptamer |
| GB202308799D0 (en) | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Neurodegenerative disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606040D0 (en) * | 1996-03-22 | 1996-05-22 | Isis Innovation | Active peptide |
| US20040038875A1 (en) * | 2000-03-29 | 2004-02-26 | Greenfield Susan Adele | Alpha 7nicotinic receptor screening assays |
| GB0028578D0 (en) * | 2000-11-23 | 2001-01-10 | Synaptica Ltd | Screening assays |
| GB0502068D0 (en) * | 2005-02-01 | 2005-03-09 | King S College London | Screening method |
| AU2006279618A1 (en) * | 2005-08-16 | 2007-02-22 | Genentech, Inc. | Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues |
| GB0708646D0 (en) * | 2007-05-04 | 2007-06-13 | Enkephala Ltd | Biologically active C-terminal fragment of acetylcholinesterase |
| EP2203746B1 (en) * | 2007-09-24 | 2013-03-06 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
| CN101530162B (zh) * | 2008-03-10 | 2011-11-23 | 北京大北农科技集团股份有限公司 | 一种新型蛋白饲料添加剂的制备方法 |
-
2015
- 2015-03-27 GB GBGB1505239.2A patent/GB201505239D0/en not_active Ceased
-
2016
- 2016-01-18 GB GB1600871.6A patent/GB2541477A/en not_active Withdrawn
- 2016-03-23 KR KR1020177027589A patent/KR102626626B1/ko active Active
- 2016-03-23 ES ES16713029T patent/ES2952723T3/es active Active
- 2016-03-23 CN CN201680021081.0A patent/CN107531796A/zh active Pending
- 2016-03-23 RU RU2017133649A patent/RU2729491C2/ru active
- 2016-03-23 EP EP16713029.3A patent/EP3274371B1/en active Active
- 2016-03-23 BR BR112017020769-9A patent/BR112017020769A2/en active Search and Examination
- 2016-03-23 WO PCT/GB2016/050804 patent/WO2016156803A1/en not_active Ceased
- 2016-03-23 JP JP2017550514A patent/JP7327897B2/ja active Active
- 2016-03-23 US US15/561,021 patent/US10954306B2/en active Active
- 2016-03-23 MX MX2017012397A patent/MX392158B/es unknown
- 2016-03-23 AU AU2016240020A patent/AU2016240020B2/en not_active Ceased
- 2016-03-23 CA CA2979972A patent/CA2979972A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016240020B2 (en) | 2022-02-17 |
| GB201600871D0 (en) | 2016-03-02 |
| JP7327897B2 (ja) | 2023-08-16 |
| RU2729491C2 (ru) | 2020-08-07 |
| US10954306B2 (en) | 2021-03-23 |
| EP3274371A1 (en) | 2018-01-31 |
| KR102626626B1 (ko) | 2024-01-17 |
| EP3274371B1 (en) | 2023-06-07 |
| RU2017133649A (ru) | 2019-04-29 |
| BR112017020769A2 (en) | 2018-06-26 |
| GB201505239D0 (en) | 2015-05-13 |
| KR20170138414A (ko) | 2017-12-15 |
| US20180051094A1 (en) | 2018-02-22 |
| JP2018516849A (ja) | 2018-06-28 |
| CA2979972A1 (en) | 2016-10-06 |
| WO2016156803A1 (en) | 2016-10-06 |
| RU2017133649A3 (enExample) | 2020-02-17 |
| ES2952723T3 (es) | 2023-11-03 |
| CN107531796A (zh) | 2018-01-02 |
| MX2017012397A (es) | 2018-01-26 |
| GB2541477A (en) | 2017-02-22 |
| AU2016240020A1 (en) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500062A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
| MX2017012397A (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| JO3692B1 (ar) | عوامل، استخدامات وطرق لعلاج مرض تنكسي عصبي | |
| JO3576B1 (ar) | أجسام مضادة لـ tau واستخداماتها | |
| WO2018017864A3 (en) | Pvrig-binding agents and uses thereof | |
| BR112022009317A2 (pt) | Anticorpos de cd73 biparatópicos | |
| TN2018000419A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof. | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| GEAP202114964A (en) | ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF | |
| CO2017001875A2 (es) | Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace | |
| EP4464317A3 (en) | Compounds and compositions and uses thereof | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| BR112016022575A2 (pt) | Composições e métodos para o tratamento de doenças neurodegenerativas | |
| CO2019002550A2 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
| MX2016008968A (es) | Compuestos organicos. | |
| MY206530A (en) | Methods for treating neurodegenerative disorders | |
| MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
| MX393805B (es) | Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. | |
| WO2016150415A8 (de) | Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz | |
| EA202192254A1 (ru) | Fcmr-связывающие молекулы и их применение | |
| EA201990493A1 (ru) | Антитела к гм-ксф и их применения |